Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
OBJECTIVE
To compare the efficacy and tolerability of metformin, rosiglitazone and gliclazide MR as monotherapy and in combination in the treatment of type 2 diabetes.


METHODS
250 patients treated with oral antidiabetic agents for at least 24 weeks in monotherapy or in combination therapy were included in this retrospective study.


RESULTS
As monotherapy the reduction of fasting plasma glucose (FPG), postprandial glycemia (PPG) and HbA1c was similar with the three drugs after 24 weeks. Among patients on combination therapy, the reduction in HbA1c, FPG and PPG was significantly lower with rosiglitazone plus metformin, as compared to metformin plus gliclazide MR or gliclazide MR plus rosiglitazone. Patients treated with rosiglitazone achieved less favorable changes in lipid profile.


CONCLUSIONS
In monotherapy all drugs were equally effective in improving glycemic control, whereas the combination of metformin plus gliclazide MR provided the best results concerning the improvement of both, glycemic control and lipid profile.
Vilar
Lucio
L
Centro de Diabetes e Endocrinologia de Pernambuco, Recife, PE, Brasil. lvilar@gmail.com <lvilar@gmail.com>
Canadas
Viviane
V
Arruda
Maria Juliana
MJ
Arahata
Carla
C
Agra
Rodrigo
R
Pontes
Lisete
L
Montenegro
Larissa
L
Vilar
Clarice Freitas
CF
Silva
Lidiane Moura e
LM
Albuquerque
José Luciano
JL
Gusmão
Amaro
A
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D005907:Gliclazide / Q000009:adverse effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D008687:Metformin / Q000009:adverse effects*; D008875:Middle Aged; D012189:Retrospective Studies; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin; D005907:Gliclazide